Ionis Pharmaceuticals IONS Equity Securities Fv Ni Accumulated Gross Unrealized Loss
Equity Securities Fv Ni Accumulated Gross Unrealized Loss at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept ions:EquitySecuritiesFvNiAccumulatedGrossUnrealizedLoss.
The official record: Ionis Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ionis Pharmaceuticals's equity securities fv ni accumulated gross unrealized loss.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ionis Pharmaceuticals's equity securities fv ni accumulated gross unrealized loss?
- Ionis Pharmaceuticals (IONS) reported equity securities fv ni accumulated gross unrealized loss of $9.8M in Q1 2026.
- How has Ionis Pharmaceuticals's equity securities fv ni accumulated gross unrealized loss changed year-over-year?
- Ionis Pharmaceuticals's equity securities fv ni accumulated gross unrealized loss decreased by 38.5% year-over-year, from $15.95M to $9.8M.
- What is the long-term trend for Ionis Pharmaceuticals's equity securities fv ni accumulated gross unrealized loss?
- Over 4 years (2021 to 2025), Ionis Pharmaceuticals's equity securities fv ni accumulated gross unrealized loss has grown at a 109.1% compound annual growth rate (CAGR), from $837K to $16.01M.
- What does equity securities fv ni accumulated gross unrealized loss mean?
- The total paper loss on equity investments that directly reduces the company's net income.
- How do you interpret equity securities fv ni accumulated gross unrealized loss?
- An increase indicates that the company's strategic equity investments are declining in value, negatively impacting reported net income.
- How does equity securities fv ni accumulated gross unrealized loss compare across companies?
- Common in companies with active venture-style investment arms or significant equity stakes in partners.